The in vivo activity and source of I-lactamase in sputum samples from 43 patients with cystic fibrosis (CF) during a 2-week antipseudomonal treatment were studied. A colorimetric method, based on the conversion of nitrocefin, was used for quantitation of the sputum ,B-lactamase activity. P-Lactamases in sputum were characterized by isoelectric focusing and inhibition profile and were compared with the ,-lactamases extracted from Pseudomonas aeruginosa isolated from the paired sputum samples. We found that the ,B-lactamase activity increased to high levels in sputum from patients with CF during the course of piperacillin, ceftazidime, cefsulodin, or imipenem therapy. Aztreonam therapy lead to opposite results because the j-lactamase activity decreased and aztreonam was able to mask j-lactamase activity by acting as an inhibitor. All sputum j-lactamases displayed characteristics indicative of a class I enzyme, identical to the (-lactamases extracted from P. aeruginosa. The presence of P-lactamase at such levels could lead to in vivo inactivation of j-lactam antibiotics. This study supports the hypothesis that P-lactamase production is an important in vivo resistance mechanism in P. aeruginosa-infected patients with CF.
rarely eradicated. ,B-Lactam antibiotics in combination with tobramycin are the drugs of choice for the treatment of these patients, but the development of resistance is a common problem (7, 9, 16) . Even when an apparently susceptible P. aeruginosa isolate is cultured from the patients prior to and during the treatment, the P-lactam antibiotics often seem to be ineffective.
There are several possible explanations for this observation, including the biofilm mode of growth and inadequate penetration of the antibiotic into the lung. Another possibility is that the P-lactam antibiotic is inactivated in the lungs by 3-lactamases. Chromosomal ,-lactamases of the Richmond and Sykes (11) class I are inducible in most strains of P. aeruginosa (7) , and the inducibilities of these enzymes are associated with several resistance problems. In a previous study (5) , we have shown a rapid emergence of resistance in P. aeruginosa in patients with CF because of in vivo selection of '-lactamase-producing strains that exhibit stable partial derepression of the class I enzyme, supporting the importance of ,-lactamase production as a major resistance mechanism in patients with CF.
The purpose of this study was to investigate the in vivo activity of P. aeruginosa ,B-lactamase in sputum from patients with CF during antipseudomonal treatment. pulmonary testing, and bacteriological investigation. The principles of the antibiotic treatment policy have previously been published in detail (7) . In summary, they are the requirement of bacteriological diagnosis based on sputum samples before chemotherapy is initiated. Bactericidal antibiotics are used for at least 14 days; it is preferable that P-lactam antibiotics (piperacillin, aztreonam, ceftazidime, cefsulodin, imipenem) or quinolones in combination with tobramycin be used. High intravenous dosages are given in accordance with the changed pharmacokinetics in patients with CF. All patients with chronic bronchopulmonary P. aeruginosa infections are admitted to the center electively every 3 to 4 months for a 2-week intravenous antibiotic course. During the 2-week course, sputum samples are investigated on days 1 (ust before treatment), 7, and 15 (at the end of treatment) in order to follow the emergence of antibiotic resistance. This may lead to a change of antibiotics to obtain optimal treatment. Sputum samples. A total of 43 patients with CF who produced large amounts of purulent (dark green) sputum (3 to 5 ml per sample) entered the study. The patients had suffered from chronic bronchopulmonary P. aeruginosa infection for more than 3 years and had a mean number of precipitating antibodies to P. aeruginosa of 31 (range, 18 to 50 normal values; 0 to 1 precipitins) (7) . The patients had previously received between 12 and 30 courses of antibiotics. The latest course was finished 3 months prior to the present study. Sputum samples obtained on days 1 (before first injection) and 15 (at the end of treatment) from the 43 consecutive patients (20 females and 23 males; age, 7 to 33 years) during a 2-week course of antipseudomonal p-lactam antibiotics therapy were used for P-lactamase determination. Twenty-one patients were treated with aztreonam (150 mg/kg of body weight per day). Seven patients were treated with piperacillin (300 mg/kg/day), eight patients were treated with imipenem-cilastatin (45 mg/kg/day), four patients were treated with ceftazidime (150 mg/kg/day), and four patients entered the study were examined for P-lactamase expression, and the MICs for these strains were determined. Six patients were treated with aztreonam, three patients were treated with piperacillin, three patients were treated with imipenem-cilastatin, one patient was treated with ceftazidime, and one patient was treated with cefsulodin; all treatments were in combination with tobramycin as previously described. Sputa from seven consecutive patients (four females and three males; age, 12 to 23 years) treated with aztreonam in combination with tobramycin obtained at day 15 were used for examination of the ability of aztreonam to mask the P-lactamase activity in the sol phases.
Sample preparation. Gram-stained smears of each sputum sample were investigated by light microscopy to ensure that samples were of sputum rather than saliva, and 10 ,ul was used for bacteriological assessment and quantitation of P. aeruginosa. The isolated colonies were identified by routine methods and for ,-lactamase preparation, were stored in semisolid peptone infusion broth stab cultures stored at room temperature in the dark. The sputum samples from the first 10 patients were divided, and one-half was immediately ultracentrifuged at 100,000 x g for 4 h at 4°C. The sol phase was removed and stored at -20°C until analysis. The other half of the sputum sample was homogenized with dithiothreitol (Sputulycin; Sigma, St. Louis, Mo.) at a final concentration at 50 ,ug/ml by a previously described method (6) , frozen at -20°C, thawed, and sonicated for four periods of 30 s with 45-s cooling periods in ice water prior to ultracentrifugation. Sonication was found to yield lower values for ,-lactamase activity and therefore was not used as a method of releasing the P-lactamases (data not shown). The sputum samples from the remaining 33 patients were immediately ultracentrifuged and subsequently stored at -20°C until they were assayed. Sputum I8-lactamase assay. The assay for measurement of P-lactamase activity in the sputum sol phases was based on conversion of the chromogenic cephalosporin nitrocefin by P-lactamase (10) by a modification of the method described by Dragicevic et al. (2) . Nitrocefin was dissolved in a small amount of dimethyl sulfoxide and diluted to 77.4 ,ug/ml with 0.1 M sodium phosphate buffer (pH 6.9). The substrate (100 ,ul) was mixed with a 50-pA volume of buffer (blank) or secretion (sol phase) to give a final concentration of 51.6 pLg/ml (10-' M). The color change yellow to red in seven periods of 30 s was determined at 492 nm with an enzyme immunoassay reader (2250 Bio-Rad Laboratories, Richmond, Calif.) at 37°C. Samples which gave a reading above the range of the standard curve (Penase, Bacillus cereus; LEO Pharmaceutical Products, Copenhagen, Denmark) were diluted and remeasured. All samples were run in the same assay. The intraassay coefficient of variation was 6.9%. The lower limit of detection was 5 mU/ml, (1 mU is defined as 1 nmol of nitrocefin hydrolyzed per minute). The result for the samples was obtained by interpolation.
Effect of albumin. As described previously (10), albumin can be responsible for a color change similar to that caused by ,-lactamases. We therefore assessed the effects of pure human albumin (Sigma) and human serum. The substrate (100 ,ul) was mixed with an equal volume of buffer (blank), fresh pooled human serum from five people, or increasing concentrations of albumin (0.10 to 5.0 mg/ml) dissolved in assay buffer. The color change was measured as described above.
Albumin content in the sol phases. The albumin content of the sol phases was determined by rocket immunoelectrophoresis. Albumin rocket immunoelectrophoresis (15) was performed in 1% human serum albumin-agarose containing rabbit antihuman albumin (0.25 f.d/cm2 of gel; Dakopatts, Copenhagen, Denmark). Dilutions of a serum pool with a known albumin content were used as standards. Electrophoresis were performed at 2 V/cm overnight by using 0.025 M sodium barbital-0.073 M Tris (pH 8.6). Plates were stained with Coomassie brilliant blue R-250.
Effect of aztreonam. The ability of aztreonam to mask the P-lactamase activity in the sputum sol phases was studied by dialyzing seven sputum sol phases with no detectable ,-lactamase activity. On day 15, sputum was obtained from seven consecutive patients with CF treated with aztreonam in combination with tobramycin. A total of 1 ml of the sputum sol phases was dialyzed against 1,000 ml of phosphate buffer at 22°C for 3 h. The buffer was exchanged and the sol phases were dialyzed for another 16 h (22°C). After dialysis, the P-lactamase activity in the sol phases was measured as described above. In addition, aztreonam was added to the sol phases (from day 15) from 15 of the patients with CF (3 patients were treated with piperacillin, 9 patients were treated with imipenem-cilastatin, 2 patients were treated with ceftazidime, and 1 patient was treated with cefsulodin; all treatments were in combination with tobramycin) to final concentrations of 0.9, 1.8, and 3.6 pug/ml. The P-lactamase activity in the sol phases was immediately measured as described above.
Preparation of P-lactamase extracts. P-Lactamase expression in 28 pairs of P. aeruginosa isolates from 14 of the 43 patients was examined in sonic extracts prepared with or without 2 h of induction with benzylpenicillin, as described previously (5).
Measurement of P-lactamase activity. The P-lactamase activities of the P. aeruginosa extracts (basal and induced enzyme activities) were measured by a direct spectrophotometric method by using nitrocefin (Becton Dickinson, Cockeysville, Md.) as the substrate (10).
Isoelectric focusing. All P. aeruginosa extracts (described above) and all sol phases were investigated by isoelectric focusing. P-Lactamases were focused in Ampholine polyacrylamide gel plates (pH 3.5 to 9.5; LKB Instruments) as described by the manufacturer. The gel was focused at 7°C with a power supply set at 1 W of constant power and 320 V limiting for 18 h; this was followed by an additional 1 h at 1 W of constant power and 400 V. To demonstrate the position of enzyme bands, filter papers (Whatman 54) soaked with nitrocefin (50 ,ug/ml) were placed on the surface of the focused gel. The enzymes were detected by the pink color on the gel and were photographed immediately. For inhibition studies, filter paper soaked with inhibitor (0.1 mM clavulanic acid and 0.1 mM cloxacillin) was placed on the surface of the focused gel. After 20 s, the paper was removed and the nitrocefin overlay was applied (14) .
Concentrations of I-lactam antibiotics in sputum. Assays of concentrations of the drug in sputum were performed by a previously described disc diffusion technique (12) . The organisms used in the assay were strains of Proteus rettgeri, Staphylococcus aureus, or nonhemolytic staphylococcus (strain EB 68). The organisms were seeded in 5% blood agar.
Standards of piperacillin, ceftazidime, cefsulodin, aztreo-nam, imipenem-cilastatin, and tobramycin were prepared in buffered saline, and sputum sol phases containing no antibiotics were used as controls.
Concentrations of tobramycin in sputum. Tobramycin could be responsible for a diminution of the diameter of the inhibition zone in the biological assay used for determination of the concentrations of ,-lactam antibiotics in sputum. We therefore assayed the sputum for aminoglycoside content Susceptibility determination of in vivo-selected P. aeruginosa. Sputum samples collected on days 1 and 15 were immediately stored at 4°C and cultured within 1 h. Homogenization with dithiothreitol (Sputulycin; Sigma) at a final concentration at 50 mg/ml was performed by a previously described method (6) . Sputum was diluted in saline and inoculated on 5% horse blood agar plates, and the P. aeruginosa colonies (CFU) were counted.
The MICs of the agents for the 28 strains (14 strains isolated on day 1 and 14 strains isolated on day 15) were determined by a routine agar plate dilution method (4 
RESULTS
Effect of serum and pure albumin on the sputum ,-lactamase assay. No detectable change in the nitrocefin color occurred in samples containing 0.1 to 5.0 mg of albumin per ml during the 3.5-min measurement period. All sputum samples contained less than 5.0 mg of albumin per ml (median, 1.4 mg/ml) (data not shown). Thus, it was not necessary to make allowances for effect of the albumin.
Bacterial assessment. All the patients produced purulent sputum (3 to 5 ml per sample) during the treatment. Microscopy and bacteriological assessment confirmed the bronchopulmonary origin as well as the fact that P. aeruginosa was the quantitatively dominating organism present in the decreased from 2,439 to 27 mU/mI and 281 to 104 mU/ml of sol phase during the treatment in these two patients.
Aztreonam was found to mask the P-lactamase activity in the sol phases from seven additional aztreonam-treated patients with CF. Prior to dialysis, no detectable 3-lactamase activity was found in the sol phases. After overnight dialysis, a significant increase in ,-lactamase activity in all seven sol phases was found (mean, 48 mU; range, 9 to 90 mU; P = 0.018). Aztreonam inhibited all the ,B-lactamase activity in all of the ,-lactamase-positive sputum sol phases at a concentration of 1.8 ,ug/ml. The median value decreased from 227 to 0 mU. j-Lactamase expression and susceptibility of in vivo-selected P. aeruginosa. All of the P. aeruginosa strains isolated on day 15 from the sputum of patients with CF obtained exhibited resistance against the P-lactam antibiotic used during the antipseudomonal treatment. The median MIC increased from 1.5 ,ug/ml (range, from 0.5 to 3.1 jig/ml) to 50 jig/ml (range, 12.5 to 200 ,g/ml) (data not shown).
All of the resistant in vivo-selected isolates showed significantly (P = 0.0001) higher levels of basal P-lactamase expression in comparison with those for the susceptible isolates. The median value increased from 385 to 838 U ( Table 3 ). The 14 strains isolated on day 1 showed wide variabilities in their basal ,-lactamase expressions: 2 strains (from patients 6 and 19) showed low basal 1-lactamase expression (19 and 22 U), 10 strains showed moderate elevated basal P-lactamase expression (94 to 693 U), and 2 strains showed extremely high basal P-lactamase expression, (1,342 and 3,852 U). All strains could be induced to higher levels of enzyme expression, up to 7,289 U; the median values increased from 385 to 3,545 U.
At day 15, this pattern changed and all the strains showed significantly (P = 0.0001) higher basal levels of 3-lactamase expression, up to 7,396 U. All strains could be induced to even higher levels of enzyme expression, up to 10,880 U. The median values increased from 838 to 6,755 U. All of the in vivo-selected resistant strains except one (that from patient 28) could be induced to significantly higher (but not the same) levels of ,-lactamase expression in comparison with those of the susceptible parent strains (P = 0.0002). The median values increased from 3,545 to 6,755 U (Table 3) .
Characterization and sources. The P-lactamase present in the sol phases and the 1-lactamase prepared from the P. aeruginosa organisms isolated from the same samples ap- Our results demonstrate that all of the in vivo-selected resistant isolates from 14 patients with CF showed stable partial derepression, producing significantly higher levels of basal ,-lactamase in comparison with those produced by the susceptible isolates. Surprisingly, the resistant in vivo-selected P. aeruginosa in sputum from the three patients treated with imipenem also showed significantly higher P-lactamase production in comparison with that produced by the susceptible isolates (13.7-fold increase). Further studies are needed to clarify the role of these P-lactamases in imipenem resistance. Sputum from two of the imipenemtreated patients did not show a significant increase during the treatment, but this does not exclude the presence of high amounts of P-lactamase inside unbroken cells, which was not measured by this method.
In vivo selection of stable partially derepressed strains may explain the increase in the P-lactamase activity in sputum, but induction in vivo also seems feasible. The resistant in vivoselected strains were induced to significantly higher levels of P-lactamase expression compared with the susceptible strains, supporting the hypothesis that in vivo induction may play an important role as a resistance mechanism. It should be noted that the ,B-lactamase activity in sputum from patients treated with piperacillin increased relatively more (up to 47-fold), to the same high levels present in sputum from patients treated with imipenem, ceftazidime, and cefsulodin. Piperacillin differs from imipenem (and ceftazidime and cefsulodin) in that it is a weak inducer in vitro (8) . This relatively higher increase in 1-lactamase activity could be caused by promoted in vivo induction in combination with selection of stable derepressed strains. Our results supports this hypothesis. The presence of P-lactamase in sputum at such high levels could lead to inactivation of P-lactam antibiotics, thus rendering them ineffective. The low P-lactam antibiotic activity (beyond therapeutic levels) found in all the sputum samples supports this hypothesis.
The ,-lactamase activity in sputum from patients treated with aztreonam showed a different pattern. In all but two of the patients, no detectable P-lactamase activity was found in sputum at day 15 (13) . The results of this study confirm this information. All the in vivo-selected resistant strains showed significantly higher levels of ,-lactamase expression in comparison with those of the susceptible parent strains.
Since all the patients enrolled in this study had suffered from chronic P. aeruginosa infection for more than 3 years and had received several antibiotic courses, the majority of the strains isolated from the sputum of patients with CF prior to treatment showed, as expected, stable derepression and resistance against most of the P-lactams used at the CF center, leaving only one or two P-lactams as the drug of choice for treatment.
In conclusion, we found that the ,B-lactamase activity increased to high levels in sputum samples from patients with CF during a 2-week course of piperacillin, ceftazidime, imipenem, and cefsulodin in combination with tobramycin. Aztreonam therapy lead to the opposite results, because the P-lactamase activity decreased, but aztreonam was found to mask the 3-lactamase activity in the sputum. All ,-lactamases displayed characteristics indicative of a class I enzyme. The presence of ,-lactamase at these high levels could lead to the in vivo inactivation of P-lactam antibiotics. This study supports the hypothesis that 3-lactamase production is an important in vivo resistance mechanism in patients with CF infected with P. aeruginosa. Since ,B-lactam antibiotics often are the drugs of choice in the treatment of patients with CF, use of an effective P-lactamase inhibitor in combination with the P-lactam antibiotic seems to be relevant.
